IRIS

Cabazitaxel Versus Docetaxel As First-Line Therapy for Patients With Metastatic Castration-Resistant Prostate Cancer: A Randomized Phase III Trial-FIRSTANA / Oudard, S; Fizazi, K; Sengeløv, L; Daugaard, G; Saad, F; Hansen, S; Hjälm-Eriksson, M; Jassem, J; Thiery-Vuillemin, A; Caffo, O; Castellano, D; Mainwaring, Pn; Bernard, J; Shen, L; Chadjaa, M; Sartor, O.. - In: JOURNAL OF CLINICAL ONCOLOGY. - ISSN 0732-183X. - 2017:35(2017), pp. 3189-3197. [10.1200/JCO.2016.72.1068]

Cabazitaxel Versus Docetaxel As First-Line Therapy for Patients With Metastatic Castration-Resistant Prostate Cancer: A Randomized Phase III Trial-FIRSTANA.

Caffo O;
2017-01-01
2017
JOURNAL OF CLINICAL ONCOLOGY
35
2-s2.0-85028322344
WOS:000411862300004
Oudard, S; Fizazi, K; Sengeløv, L; Daugaard, G; Saad, F; Hansen, S; Hjälm-Eriksson, M; Jassem, J; Thiery-Vuillemin, A; Caffo, O; Castellano, D; Mainwa...espandi
Cabazitaxel Versus Docetaxel As First-Line Therapy for Patients With Metastatic Castration-Resistant Prostate Cancer: A Randomized Phase III Trial-FIRSTANA / Oudard, S; Fizazi, K; Sengeløv, L; Daugaard, G; Saad, F; Hansen, S; Hjälm-Eriksson, M; Jassem, J; Thiery-Vuillemin, A; Caffo, O; Castellano, D; Mainwaring, Pn; Bernard, J; Shen, L; Chadjaa, M; Sartor, O.. - In: JOURNAL OF CLINICAL ONCOLOGY. - ISSN 0732-183X. - 2017:35(2017), pp. 3189-3197. [10.1200/JCO.2016.72.1068]
File in questo prodotto:
Non ci sono file associati a questo prodotto.

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/11572/477774
 Attenzione

Attenzione! I dati visualizzati non sono stati sottoposti a validazione da parte dell'ateneo

Citazioni
  • ???jsp.display-item.citation.pmc??? ND
  • Scopus 316
  • ???jsp.display-item.citation.isi??? 278
  • OpenAlex 353
social impact